H. Hatano

Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond

Simple Summary Classical EGFR mutations have transformed the management of non-small cell lung cancer across metastatic, resectable, and unresectable locally advanced settings. This review traces the evolution from early-generation EGFR tyrosine kinase inhibitors to osimertinib and contemporary combination regimens, an...